6ix — Find Your Next Investment

Discover investor relations events, company profiles, and opportunities on 6ix. Connect with public companies and attend live investor events.

Please enable JavaScript to use all features of 6ix.com.

Oorspronkelijke tekst

Deze vertaling beoordelen

Je feedback wordt gebruikt om Google Translate te verbeteren

Latest Press Releases

Time	Headline
40m ago	Nayax to Report 2026 Q1 Earnings on May 12, 2026
1h ago	CC Capital and OneIM Complete Acquisition of Insignia Financial Limited, Australia's Leading Diversified Wealth Management Group
1h ago	Canadian Gold Resources Strengthens Board with Capital Markets Veteran Kenneth Chernin
1h ago	Waraba Gold Signs Binding Agreement to Establish Joint Venture Relating to Tengrela South Exploration Permit Application in Cote d'Ivoire
1h ago	Sierra Madre Announces Shareholder Approval of Acquisition of Del Toro Silver Mine

About

Allogene Therapeutics Inc (NASDAQ:ALLO) — investor relations, events, news, and company updates on 6ix.

Latest News

Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia

Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026

Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock

Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases

Allogene Therapeutics Announces Pricing of Public Offering of Common Stock

Financials

Revenue

$0

Market Cap

$633.82 M

EPS

-0.87

Community Chat

Ask AI